Project Grant K25HL186244
Award Date 8/17/26
Completion Date 7/31/30
Dollars Obligated $101K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $704,851 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance tissue characterization methods for prognostication and therapeutic response prediction in functional tricuspid regurgitation. The project leverages newly developed CMR techniques optimized for the thin-walled right ventricle, including high-resolution 3D navigator late...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded Cornell University $734,475 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanobiological regulation of ventricular maturation. The research will test the hypothesis that local mechanical stress operates a Piezo-Notch-YAP mechanobiological switch governing temporal compact and trabecular ventricular wall growth versus structural maturation dynamics. The...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $818,022 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize endothelin-1 (ET-1) and its receptor (ET-RA) as cardiomyocyte proliferation inhibitors in neonatal mice. The research aims to identify mechanisms by which extracellular inhibitory factors suppress heart cell proliferation, with the long-term goal of enabling therapeutic strategies to...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $1,657,587 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect molecular pathways controlling human pacemaker development. The recipient will conduct research aimed at identifying key transcriptional regulators of sinoatrial node (SAN) differentiation using CRISPR interference and activation in human pluripotent stem cells, then validate findings in...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $133,221 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate precision electrophysiology imaging techniques for localizing cardiac arrhythmias. The recipient will use computed tomography and echocardiography imaging combined with electroanatomical mapping data to create three-dimensional visualization of arrhythmia...
- The National Heart, Lung, and Blood Institute awarded Northwestern University $696,259 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop flexible electronics and optogenetics approaches for real-time arrhythmic profiling of engineered heart tissues. The project runs through April 30, 2031, with work performed in Chicago, Illinois. The award funds development of non-invasive arrhythmia assessment methods for human induced pluripotent stem cell–derived...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $760,465 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop deep learning methods that advance cardiac magnetic resonance strain imaging for personalized cardiac resynchronization therapy treatment planning. The award funds development of deep strain networks to rapidly and accurately predict myocardial displacements from cardiac magnetic resonance imaging, addressing...
- The National Heart, Lung, and Blood Institute awarded Case Western Reserve University $760,476 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a low-field magnetic resonance imaging guided robotic catheter system for ventricular tachycardia ablation. The project addresses recurrence rates as high as 37% in ventricular tachycardia (VT) ablation procedures, particularly in patients with extensive structural or non-ischemic heart disease. The system...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $767,249 on June 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate computational models for designing organ-scale vasculature in biomanufactured cardiac tissues. The project addresses the need for patient-specific engineered tissues to repair complex congenital heart defects, particularly large ventricular septal defects where current surgical approaches...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...